The human body is colonized by a wide range of microorganisms. The field of viromics has
expanded since the first reports on the detection of viruses via metagenomic sequencing in …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Background Accumulating evidence has revealed that the gut microbiota influences the
effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. As a part of the …

Simple Summary Microbial dysbiosis has been credited as one of the contributing factors to
the development and progression of gastrointestinal tract cancer. The altered microbiota …

Colorectal cancer (CRC) is the second leading cause of cancer death in the world.
Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell …

Colorectal carcinoma is the third most common cancer in developed countries and the
second leading cause of cancer-related mortality. Interest in the influence of the intestinal …

Immunotherapy in the metastatic setting has drastically altered the landscape of treatment
for various types of malignancy, including colorectal cancer. The category of immune …

The symbiotic interaction between gut microbiota and the digestive tract is an important
factor in maintaining the intestinal environment balance. Colorectal cancer (CRC) is a …

Metabolic syndrome encompasses amongst other conditions like obesity and type-2
diabetes and is associated with gut microbiome (GM) dysbiosis. Fecal microbiota …

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and poses a
major burden on the human health worldwide. At the moment, treatment of CRC consists of …